Approved HCV Drugs
Approved HCV Drugs
Merck Plans to Discontinue Boceprevir for Hepatitis C by December 2015
- Details
- Category: Approved HCV Drugs
- Published on Wednesday, 21 January 2015 00:00
- Written by Merck
Merck will stop selling its HCV protease inhibitor boceprevir (Victrelis) by December of this year, and no new patients should be started on the drug, the company announced in a recent "Dear Healthcare Professional" letter. While the first-generation HCV protease inhibitors improved the effectiveness of pegylated interferon plus ribavirin, they are no match in terms of efficacy or tolerability for the newer interferon-free combinations approved over the past 2 years.
2. Harvoni and Viekira Pak: Effective Oral Combinations for HCV Genotype 1
- Details
- Category: Approved HCV Drugs
- Published on Monday, 12 January 2015 00:00
- Written by HIVandHepatitis.com
2014 saw the long-awaited U.S. Food and Drug Administration (FDA) approval of new interferon-free combination regimens for people with genotype 1 chronic hepatitis C: Gilead Sciences sofosbuvir/ledipasvir coformulation (Harvoni) in October and AbbVie's paritaprevir/ritonavir/ombitasvir plus dasabuvir regimen (Viekira Pak, formerly known as "3D") in late December.
AASLD 2014: Sofosbuvir/ Ledipasvir Cures Most Previously Treated HCV Patients with Cirrhosis
- Details
- Category: Approved HCV Drugs
- Published on Tuesday, 09 December 2014 00:00
- Written by Liz Highleyman
Difficult-to-treat hepatitis C patients with liver cirrhosis who were not cured with a prior course of therapy with first-generation HCV protease inhibitors had a sustained virological response rate of 97% when retreated with sofosbuvir/ledipasvir (Harvoni) for 24 weeks, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last month in Boston. Sofosbuvir/ledipasvir also worked worked well for people previously treated with other sofosbuvir-containing regimens.
3. High Hepatitis C Treatment Cost Leads to Restrictions, Sets Off Price War
- Details
- Category: Approved HCV Drugs
- Published on Monday, 12 January 2015 00:00
- Written by HIVandHepatitis.com
The high cost of new interferon-free hepatitis C treatments has raised concerns about how public payers and private insurers will be able to afford them and sparked a more general discussion about the cost of pharmaceuticals in a changing healthcare landscape.
AASLD 2014: DAAs Show Good Cure Rates and Liver Function Improvement for Transplant Recipients with Recurrent HCV
- Details
- Category: Approved HCV Drugs
- Published on Tuesday, 25 November 2014 00:00
- Written by Liz Highleyman
A variety of interferon-free regimens containing the direct-acting antivirals sofosbuvir (Sovaldi), simeprevir (Olysio), and daclatasvir (Daklinza) led to high sustained virological response rates, often improved liver function, and were generally safe and reasonably well-tolerated by liver transplant recipients with hepatitis C recurrence, one of the most difficult populations to treat, according to several presentations at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this month in Boston.
More Articles...
- AASLD 2014: Sofosbuvir/ Ledipasvir + Ribavirin Cures Most Post-Transplant HCV Recurrence
- AASLD 2014: Sofosbuvir + Simeprevir Shows Good Results in Real-World Use
- AASLD 2014: AbbVie 3D Regimen and Sofosbuvir/ Ribavirin Show High Cure Rates for HIV/HCV Coinfection
- AASLD 2014: Grazoprevir/ Elbasvir Combo Shows High Cure Rates, Including Cirrhotics and Coinfected
Web Design and Development by